TEMPI Syndrome is a novel orphan disease where the person share five characteristics from which the acronym is derived: telangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collection, and intrapulmonary shunting.
Contents
Description of symptoms
The four men and two women were all diagnosed at middle age. The symptoms were slowly and steadily progressive. Telangiectasias developed over the face, trunk and arms. Increased serum erythropoietin levels, eventually exceeding 5000 mU /ml, preceded the intrapulmonary shunting and the development of hypoxemia. Sampling of the perinephric fluid revealed a clear, serous fluid with low levels of protein, few leukocytes and no cholesterol or triglycerides. An IgG monoclonal gammopathy was implicated in the four patients tested (with an associated kappa light chain in all three patients tested). Spontaneous venous thromboses occurred in three patients, two of whom also had spontaneous intracranial bleeding in the absence of blood vessels malformations.
Since then more patients with the syndrome have been reported. The cause of the syndrome is unknown.
Treatment
Complete and partial disappearance of the symptoms of the TEMPI syndrome was reported with the drug bortezomib.
History
In 2010, the case of a man with unexplained erythrocytosis and perinephric fluid collection as main features was described in the Case Records of the Massachusetts General Hospital. As a consequence two strikingly similar cases were identified and a review of the literature revealed three more patients with similar characteristics.
As of December 2014, a total of 9 patients worldwide with the TEMPI syndrome have been identified (D.B.Sykes, Personal Communication).
In terms of their therapy: